4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Notice of Nasdaq Delisting for Heron Therapeutics, Inc.
Stockholders Elect Seven Directors at Heron Therapeutics Annual Meeting
U.S. District Court Issues Decision Regarding Patents
Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Collard Amendment - CEO Craig Collard's Employment Agreement Updated
Announces Fourth Quarter and Full-Year 2025 Financial Results
Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
Announces Q3 2025 Financial Results and Highlights Commercial Progress
Q1
FY 2024
Q3
Q2
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload